Literature DB >> 33419780

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).

Helen X Chen1, Minkyung Song2, Holden T Maecker3, Sacha Gnjatic4, David Patton5, J Jack Lee6, Stacey J Adam7, Radim Moravec8,9, Xiaole Shirley Liu10, Ethan Cerami10, James Lindsay10, Ming Tang10, F Stephen Hodi11, Catherine J Wu12,13,14,15, Ignacio I Wistuba16, Gheath Al-Atrash17, Chantale Bernatchez18, Sean C Bendall19, Stephen M Hewitt20, Elad Sharon2, Howard Streicher2, Rebecca A Enos21, Melissa D Bowman21, Valerie M Tatard-Leitman21, Beatriz Sanchez-Espiridion16, Srinika Ranasinghe11, Mina Pichavant3, Diane M Del Valle4, Joyce Yu10, Sylvie Janssens21, Jenny Peterson-Klaus7, Cathy Rowe5,22, Gerold Bongers23, Robert R Jenq17,24, Chia-Chi Chang24, Jeffrey S Abrams2, Margaret Mooney2, James H Doroshow25, Lyndsay N Harris8, Magdalena Thurin26.   

Abstract

PURPOSE: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immuno-oncology biomarkers. Variability in assay performance further limits comparison and interpretation of data across studies and laboratories. EXPERIMENTAL
DESIGN: To enable a systematic approach to biomarker identification and correlation with clinical outcome across trials, the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network was established through support of the Cancer MoonshotSM Initiative of the National Cancer Institute (NCI) and the Partnership for Accelerating Cancer Therapies (PACT) with industry partners via the Foundation for the NIH.
RESULTS: The CIMAC-CIDC Network is composed of four academic centers with multidisciplinary expertise in cancer immunotherapy that perform validated and harmonized assays for immunoprofiling and conduct correlative analyses. A data coordinating center (CIDC) provides the computational expertise and informatics platforms for the storage, integration, and analysis of biomarker and clinical data.
CONCLUSIONS: This overview highlights strategies for assay harmonization to enable cross-trial and cross-site data analysis and describes key elements for establishing a network to enhance immuno-oncology biomarker development. These include an operational infrastructure, validation and harmonization of core immunoprofiling assays, platforms for data ingestion and integration, and access to specimens from clinical trials. Published in the same volume are reports of harmonization for core analyses: whole-exome sequencing, RNA sequencing, cytometry by time of flight, and IHC/immunofluorescence. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33419780      PMCID: PMC8491462          DOI: 10.1158/1078-0432.CCR-20-3241

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

Review 1.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

2.  Immuno-oncology drug development goes global.

Authors:  Jia Xin Yu; Vanessa M Hubbard-Lucey; Jun Tang
Journal:  Nat Rev Drug Discov       Date:  2019-11       Impact factor: 84.694

3.  From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline.

Authors:  Geraldine A Van der Auwera; Mauricio O Carneiro; Christopher Hartl; Ryan Poplin; Guillermo Del Angel; Ami Levy-Moonshine; Tadeusz Jordan; Khalid Shakir; David Roazen; Joel Thibault; Eric Banks; Kiran V Garimella; David Altshuler; Stacey Gabriel; Mark A DePristo
Journal:  Curr Protoc Bioinformatics       Date:  2013

4.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Authors:  Whijae Roh; Pei-Ling Chen; Alexandre Reuben; Christine N Spencer; Peter A Prieto; John P Miller; Vancheswaran Gopalakrishnan; Feng Wang; Zachary A Cooper; Sangeetha M Reddy; Curtis Gumbs; Latasha Little; Qing Chang; Wei-Shen Chen; Khalida Wani; Mariana Petaccia De Macedo; Eveline Chen; Jacob L Austin-Breneman; Hong Jiang; Jason Roszik; Michael T Tetzlaff; Michael A Davies; Jeffrey E Gershenwald; Hussein Tawbi; Alexander J Lazar; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Sapna P Patel; Scott E Woodman; Rodabe N Amaria; Victor G Prieto; Jianhua Hu; Padmanee Sharma; James P Allison; Lynda Chin; Jianhua Zhang; Jennifer A Wargo; P Andrew Futreal
Journal:  Sci Transl Med       Date:  2017-03-01       Impact factor: 17.956

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 7.  The Partnership for Accelerating Cancer Therapies.

Authors:  Rebecca G Baker; Axel X Hoos; Stacey J Adam; David Wholley; James H Doroshow; Douglas R Lowy; Lawrence A Tabak; Francis S Collins
Journal:  Cancer J       Date:  2018 May/Jun       Impact factor: 3.360

8.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

9.  Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Authors:  Teofila Seremet; Alexander Koch; Yanina Jansen; Max Schreuer; Sofie Wilgenhof; Véronique Del Marmol; Danielle Liènard; Kris Thielemans; Kelly Schats; Mark Kockx; Wim Van Criekinge; Pierre G Coulie; Tim De Meyer; Nicolas van Baren; Bart Neyns
Journal:  J Transl Med       Date:  2016-08-02       Impact factor: 5.531

10.  ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline.

Authors:  Qian Qin; Shenglin Mei; Qiu Wu; Hanfei Sun; Lewyn Li; Len Taing; Sujun Chen; Fugen Li; Tao Liu; Chongzhi Zang; Han Xu; Yiwen Chen; Clifford A Meyer; Yong Zhang; Myles Brown; Henry W Long; X Shirley Liu
Journal:  BMC Bioinformatics       Date:  2016-10-03       Impact factor: 3.169

View more
  1 in total

Review 1.  Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.

Authors:  Evangelos Tzoras; Ioannis Zerdes; Nikos Tsiknakis; Georgios C Manikis; Artur Mezheyeuski; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.